Background Major randomized trials assessing non–vitamin K antagonist oral
anticoagulants (NOAC s) for stroke prevention in atrial fibrillation generally excluded …

Background and Purpose—Several randomized trials and real-world studies have reported
the efficacy and safety of non–vitamin K antagonist oral anticoagulants (NOACs) in Asian …

Background: Data of non-vitamin K antagonist oral anticoagulants (NOACs) in current
management of atrial fibrillation (AF) are predominantly derived from North American and …

The role of non-vitamin K antagonist oral anticoagulants (NOACs) in stroke prevention
remains unclear in Asian patients with atrial fibrillation (AF). Therefore, we performed a meta …

Background This meta-analysis aimed to evaluate the efficacy and safety of non-vitamin K
antagonist oral anticoagulants (NOACs) versus vitamin K antagonists (VKAs) in secondary …

Background: Recent observational studies have compared effectiveness and safety profiles
between non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in patients with …

Background and Purpose—Evidence from the real-world setting complements evidence
coming from randomized controlled trials. We aimed to summarize all available evidence …

Importance Current guidelines recommend the use of non–vitamin K antagonist oral
anticoagulants (NOACs) for stroke prevention in patients with atrial fibrillation (AF). Data …

The non-vitamin K antagonist oral anticoagulants (NOACs) have been increasingly
prescribed in clinical practice for stroke prevention in patients with nonvalvular atrial …

Background Patients with atrial fibrillation (AF) require oral anticoagulation to prevent
ischemic stroke. However, oral anticoagulation may cause bleeding, and patients with AF …